Log In
Print
BCIQ
Print
Print this Print this
 

Egalet-001

  Manage Alerts
Collapse Summary General Information
Company Egalet Corp.
DescriptionAbuse-deterrent, extended-release, oral formulation of morphine
Molecular Target Mu opioid receptor (OPRM1) (MOR)
Mechanism of ActionMu opioid receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPivotal
Standard IndicationPain
Indication DetailsTreat moderate to severe chronic pain
Regulatory Designation

U.S. - Fast Track (Treat moderate to severe chronic pain)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today